Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: A meta-analysis

Journal of the National Cancer Institute

Volumn 105, Issue 21, 2013, Pages 1667-1670

  Paoletti, Xavier ^a   Oba, Koji ^b   Bang, Yung Jue ^c   Bleiberg, Harry ^d   Boku, Narikazu ^e   Bouché, Olivier ^f   Catalano, Paul ^g   Fuse, Nozomu ^h   Michiels, Stefan ⁱ   Moehler, Markus ^j   Morita, Satoshi ^k   Ohashi, Yasuo ^l   Ohtsu, Atsushi ^h   Roth, Arnaud ^m   Rougier, Philippe ⁿ   Sakamoto, Junichi ^o   Sargent, Daniel ^p   Sasako, Mitsuru ^h   Shitara, Kohei ^q   Thuss Patience, Peter ^r   Van Cutsem, Eric ^s   Burzykowski, Tomasz ^t   Buyse, Marc ^t,u   more..

^a INSERM U900   (France)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c Seoul National University   (South Korea)

^d JULES BORDET INSTITUTE   (Belgium)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SERVICE DE DERMATOLOGIE   (France)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j JOHANNES GUTENBERG UNIVERSITY   (Germany)

^k YOKOHAMA CITY UNIVERSITY   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

^m UNIVERSITY HOSPITAL   (Switzerland)

ⁿ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^o Tokai Central Hospital of the Mutual Aid Association of Public School Teachers   (Japan)

^p MAYO CLINIC   (United States)

^q AICHI CANCER CENTER HOSPITAL   (Japan)

^r CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^s UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^t HASSELT UNIVERSITY   (Belgium)

^u INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; MATUZUMAB; TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; CORRELATION COEFFICIENT; EXPERIMENTAL THERAPY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; TREATMENT RESPONSE; TUMOR GROWTH; VALIDATION PROCESS;

BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84890486267     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt269     Document Type: Article

References (40)

1. Oba K, Paoletti X, Bang YJ, et al. Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-Analysis. Eur J Cancer. 2013;49(7):1565-1577.
2. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101(23):1642- 1649.
3. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987-1992.
4. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25(33):5218-5224.
5. GASTRIC. Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-Analysis. Eur J Cancer. 2013; 49(7):1565-1577
6. Stewart LA, Clarke MJ. Practical methodology of meta-Analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med. 1995;14(19):2057-2079.
7. Burzykowski T, Molenberghs G, Buyse M, Geys H. Validation of surrogate endpoints in multiple randomized clinical trials with failure time endpoints. J R Stat Soc Series C Appl Stat. 2001; 50(4): 405-422.
8. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-Analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-2834.
9. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebocontrolled phase III study. J Clin Oncol.; 2011; 29(30):3968-3976.
10. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.
11. Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: A randomised, multicentre open-label phase II study. Ann Oncol.; 2010; 21(11):2213-2219.
12. Douglass HO Jr, Lavin PT, Goudsmit A, Klaassen DJ, Paul AR. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol. 1984;2(12):1372-1381.
13. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985;253(14):2061-2067.
14. Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin -A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991;9(5):827-831.
15. Kyoto Research Group for Chemotherapy of Gastric Aancer. A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4'-epirubicin (FPEPIR). Anticancer Res. 1992;12(6B):1983-1988.
16. Cullinan SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol. 1994;12(2):412-416.
17. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163-168.
18. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000;18(14):2648-2657.
19. Kim TW. A prospective randomized phase III trial of 5-fluorouracil and cusplatin (FP) versus epirubicin, cisplatin, and 5-FU (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC). Eur J Cancer. 2001; 47(3)S314.
20. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21(1):54-59.
21. Koizumi W, Fukuyama Y, Fukuda T, et al. Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer. Anticancer Res. 2004;24(4):2465-2470.
22. Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol. 2004;15(12):1773-1781.
23. Bouche O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005;16(9):1488-1497.
24. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23(24):5660-5667.
25. Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer. 2005;92(12):2122-2128.
26. Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: A randomized phase II study. J Clin Oncol. 2005;23(3):494-501.
27. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997.
28. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: A randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25(22):3217-3223.
29. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19(8):1450-1457.
30. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol. 2009;10(11):1063-1069.
31. Burzykowski T, Molenberghs G, Buyse M. The Evaluation of Surrogate Endpoints. New York: Springer; 2006.
32. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547-1553.
33. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435-1442.
34. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
35. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666-673.
36. Jeung HC, Rha SY, Im CK, et al. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer. 2011;117(10):2050-2057.
37. Moehler MH, Siebler J, Hoehler T, Janssen J, Wein A, Menges M. CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase II study. J Clin Oncol. 2004; 22(14S): 4064.
38. Park SH, Nam E, Park J, et al. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Ann Oncol. 2008;19(4):729-733.
39. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996-2004.
40. Burzykowski T, Bang Y. Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-Analysis. J Clin Oncol. 2009;27(15s):abstract 4517.